Related references
Note: Only part of the references are listed.Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines
Haiyang Zhang et al.
SCIENTIFIC REPORTS (2019)
Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
Yu-Hsuan Chen et al.
CANCERS (2019)
A rectal cancer organoid platform to study individual responses to chemoradiation
Karuna Ganesh et al.
NATURE MEDICINE (2019)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
Fei Shi et al.
ONCOTARGET (2018)
Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer
Sieske Hoendervangers et al.
EJSO (2018)
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Maxime J. M. van der Valk et al.
LANCET (2018)
Additive cytotoxic effects of radiation and mTOR inhibitors in a cervical cancer cell line
Daniele Xavier Assad et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
SRT1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells
Daryoush Fatehi et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review
Francesca De Felice et al.
NEOPLASIA (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Drug resistance and new therapies in colorectal cancer
Kevin Van der Jeught et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?
Tomas Kazda et al.
RADIOLOGY AND ONCOLOGY (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Vivek Narayan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer
Jung Hee Park et al.
ONCOTARGET (2017)
Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo
Chih-Chia Yu et al.
Oncotarget (2017)
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)
Fabio Gelsomino et al.
CLINICAL COLORECTAL CANCER (2017)
PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)
Natalie A. Lockney et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2017)
Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management
Simon Gollins et al.
COLORECTAL DISEASE (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway
Meng Wang et al.
CANCER RESEARCH (2017)
A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I
Andreia Cristina de Melo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature
Beatrice Detti et al.
JOURNAL OF CHEMOTHERAPY (2016)
Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule
Cholpon S. Djuzenova et al.
ONCOTARGET (2016)
Addressing intra-tumoral heterogeneity and therapy resistance
Brad Rybinski et al.
ONCOTARGET (2016)
Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells
Marina Holler et al.
PLOS ONE (2016)
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Michael Spiotto et al.
SCIENCE IMMUNOLOGY (2016)
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
E. Deutsch et al.
ANNALS OF ONCOLOGY (2015)
Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer
Yu-Hsuan Chen et al.
CANCER LETTERS (2015)
Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Andrew J. Leiker et al.
CLINICAL CANCER RESEARCH (2015)
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
Aki Miyasaka et al.
GYNECOLOGIC ONCOLOGY (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection
Kyle C. Cuneo et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer
Jeroen Buijsen et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
Tongxin Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
Eun Jung Choi et al.
BMC CANCER (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
Role of AKT signaling in DNA repair and clinical response to cancer therapy
Qun Liu et al.
NEURO-ONCOLOGY (2014)
Signaling through cyclin D-dependent kinases
Y. J. Choi et al.
ONCOGENE (2014)
DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy
Sean P. Pitroda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
L. Chang et al.
CELL DEATH & DISEASE (2014)
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
Wei-Lin Liu et al.
ONCOTARGET (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions
Sebastian Kuger et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2014)
NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro
Wen-juan Wang et al.
ACTA PHARMACOLOGICA SINICA (2013)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2013)
NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3
Wenjie Zhu et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
Eun Ju Kim et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial
David Azria et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin
Rebecca A. Dumont et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Inhibition of the PI3K/AKT-NF-κB Pathway With Curcumin Enhanced Radiation-Induced Apoptosis in Human Burkitt's Lymphoma
Qiao Qiao et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2013)
Push back to respond better: regulatory inhibition of the DNA double-strand break response
Stephanie Panier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
Vincent A. Potiron et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up
Julien Vignard et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Shielding Broken DNA for a Quick Fix
Jiri Lukas et al.
SCIENCE (2013)
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
Sebastian Kuger et al.
TRANSLATIONAL ONCOLOGY (2013)
Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment
Svenja Thies et al.
FRONTIERS IN ONCOLOGY (2013)
Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature
Emmanouil Fokas et al.
CANCER RESEARCH (2012)
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma
Y. Edden et al.
COLORECTAL DISEASE (2012)
Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer
Helena J. Mauceri et al.
ONCOLOGY REPORTS (2012)
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
Emmanouil Fokas et al.
RADIATION ONCOLOGY (2012)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
Bipasha Mukherjee et al.
NEOPLASIA (2012)
Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
George J. Cerniglia et al.
MOLECULAR PHARMACOLOGY (2012)
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
K. J. Harrington et al.
BRITISH JOURNAL OF CANCER (2011)
NORTH CENTRAL CANCER TREATMENT GROUP PHASE I TRIAL N057K OF EVEROLIMUS (RAD001) AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Jann N. Sarkaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts
Alexandre Bozec et al.
ORAL ONCOLOGY (2011)
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas et al.
LANCET ONCOLOGY (2010)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla et al.
LANCET ONCOLOGY (2010)
Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology Revisited
Frank Pajonk et al.
STEM CELLS (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
R. Diaz et al.
BRITISH JOURNAL OF CANCER (2009)
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
Georgia Konstantinidou et al.
CANCER RESEARCH (2009)
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
James D. Murphy et al.
CLINICAL CANCER RESEARCH (2009)
mTOR signaling at a glance
Mathieu Laplante et al.
JOURNAL OF CELL SCIENCE (2009)
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells
Hui-Fang Li et al.
RADIATION ONCOLOGY (2009)
Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
Kwang Woon Kim et al.
AUTOPHAGY (2008)
Class IPI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
Remko Prevo et al.
CANCER RESEARCH (2008)
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
Philipp C. Manegold et al.
CLINICAL CANCER RESEARCH (2008)
Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer
J. Suarez et al.
COLORECTAL DISEASE (2008)
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
Gary D. Kao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
Li Ma et al.
CELL (2006)
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer
C Rödel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines
IA Kim et al.
CANCER RESEARCH (2005)
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
ET Shinohara et al.
ONCOGENE (2005)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
L Ma et al.
CELL (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas
JL Nakamura et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
The role of radiotherapy in treatment of stage I non-small cell lung cancer
XY Qiao et al.
LUNG CANCER (2003)
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure
AV D'Amico et al.
JOURNAL OF UROLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Share Paper
